A Phase 4 interventional study of Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine and Separate vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in Influenza and Pneumonia, sponsored by Sinovac Biotech Co., Ltd. Completed at 4 sites in China. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-25.
Sponsored by Sinovac Biotech Co., Ltd · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Influenza, Human by Sinovac Biotech Co., Ltd — 2 open to participants now, 3 under way, none of them phase 3. Influenza, Human · Sinovac Biotech Co., Ltd.
Among the 27 studies in Influenza, Human by Sinovac Biotech Co., Ltd, this one is the 2nd largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2021, is one of 14 in phase 4, and was the 19th registered.
2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →2 of the 27 studies in Influenza, Human by Sinovac Biotech Co., Ltd are open now, in 1 country. Recruiting first, the newest first:
Sinovac Biotech Co., Ltd · Sites in China
Ages 18–45 · Women only · Healthy volunteers
Sinovac Biotech Co., Ltd · Sites in China
Ages 6 mo+ · Healthy volunteers
By country, each count listing its studies:
Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2021.
This study's enrollment of 3,000 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 400 across the 25 interventional studies. Of the 24 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sinovac Biotech Co., Ltd is the lead sponsor of 93 studies on the registry; 18 are open to participants now.
2 of the studies in Influenza, Human by Sinovac Biotech Co., Ltd that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07889193Sinovac Biotech Co., LtdPhase I Clinical Trial of Trivalent Inactivated Split Influenza Virus Vaccine (MDCK Cell) | 2026-12 |
| NCT07832201Sinovac Biotech Co., LtdA Phase IV Clinical Trial of Influenza Vaccine (Split Virion), Inactivatedin (Anflu®) Pregnant Women (AnFLU-PREG) | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Influenza, Human by Sinovac Biotech Co., Ltd, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is an open-label,single center phase Ⅳ clinical trial of combined immunization with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine.The purpose of this study is to evaluate the safety and immunogenicity of combined immunization with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in the elderly aged 60 years and above.
This study is an open-label,single center,phase IV clinical trial in the elderly aged 60 Years and above.The experimental vaccines were manufactured by Sinovac Biotech Co., Ltd. A total of 3000 subjects will be enrolled,the safety and immunogenicity of combined immunization were evaluated in 480 subjects,and the Safety observation of combined immunization was evaluated in the extended safety group, which included 2520 subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
160 subjects received one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.
Biological: Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine
There were two subgroups in non combined immunization group,and 160 subjects in each subgroup.The non combined immunization subgroup 1 received one dose of quadrivalent influenza vaccine on day 0 and one dose of 23-valent pneumococcal polysaccharide vaccine on day 28.The non combined immunization subgroup 2 received one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of quadrivalent influenza vaccine on day 28.
Biological: Separate vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine
2520 subjects were enrolled and received one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.
Biological: Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine
Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.
Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0 and one dose of 23-valent pneumococcal polysaccharide vaccine on day 28 in subgroup 1,and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of quadrivalent influenza vaccine on day 28 in subgroup 2.
Immunogenicity index of Geometric mean titer(GMT) of influenza HI antibodies
GMT of influenza HI antibodies for each influenza strain at 28 days after combined vaccination .
Time frame: 28 days after combined vaccination
Immunogenicity index of the seroconversion rates of influenza HI antibodies
Seroconversion rate of influenza HI antibodies for each influenza strain at 28 days after combined vaccination.
Time frame: 28 days after combined vaccination
Immunogenicity index of Geometric Mean Increase (GMI) of influenza HI antibodies
GMI of influenza HI antibodies for each influenza strain at 28 days after combined vaccination.
Time frame: 28 days after combined vaccination
Immunogenicity index of seropositivity rates of influenza HI antibodies
Seropositivity rates of influenza HI antibodies for each influenza strain at 28 days after combined vaccination.
Time frame: 28 days after combined vaccination
Immunogenicity index of Geometric Mean Concentration (GMC) for 23 serotypes specificity of pneumococcal IgG antibody
GMC for 23 serotypes specificity of pneumococcal IgG antibody at 28 days after combined vaccination.
Time frame: 28 days after combined vaccination
Immunogenicity index-seroconversion rates for 23 serotypes specificity of pneumococcal IgG antibody
Seroconversion rates for 23 serotypes specificity of pneumococcal IgG antibody at 28 days after combined vaccination.
Time frame: 28 days after combined vaccination
Immunogenicity index-GMI for 23 serotypes specificity of pneumococcal IgG antibody
GMI for 23 serotypes specificity of pneumococcal IgG antibody at 28 days after combined vaccination.
Time frame: 28 days after combined vaccination
Geometric mean titer(GMT) of influenza HI antibodies
GMT of influenza HI antibodies for each influenza strain at 28 days after a single injection of quadrivalent influenza vaccine.
Time frame: 28 days after a single injection of quadrivalent influenza vaccine
Seroconversion rates of influenza HI antibodies
Seroconversion rates of influenza HI antibodies for each influenza strain at 28 days after a single injection of quadrivalent influenza vaccine.
Time frame: 28 days after a single injection of quadrivalent influenza vaccine
Geometric Mean Increase (GMI) of influenza HI antibodies
GMI of influenza HI antibodies for each influenza strain at 28 days after a single injection of quadrivalent influenza vaccine.
Time frame: 28 days after a single injection of quadrivalent influenza vaccine
Seropositivity rates of influenza HI antibodies
Seropositivity rates of influenza HI antibodies for each influenza strain at 28 days after a single injection of quadrivalent influenza vaccine.
Time frame: 28 days after a single injection of quadrivalent influenza vaccine
Geometric Mean Concentration (GMC) for 23 serotypes specificity of pneumococcal IgG antibody
GMC for 23 serotypes specificity of pneumococcal IgG antibody at 28 days after a single injection of 23-valent pneumococcal polysaccharide vaccine.
Time frame: 28 days after a single injection of 23-valent pneumococcal polysaccharide vaccine
Seroconversion rates for 23 serotypes specificity of pneumococcal IgG antibody
Seroconversion rates for 23 serotypes specificity of pneumococcal IgG antibody at 28 days after a single injection of 23-valent pneumococcal polysaccharide vaccine.
Time frame: 28 days after a single injection of 23-valent pneumococcal polysaccharide vaccine
GMI for 23 serotypes specificity of pneumococcal IgG antibody
GMI for 23 serotypes specificity of pneumococcal IgG antibody at 28 days after a single injection of 23-valent pneumococcal polysaccharide vaccine.
Time frame: 28 days after a single injection of 23-valent pneumococcal polysaccharide vaccine
Safety index-incidence of adverse reactions
Incidence of adverse reactions at 0\~7 after combined immunization with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine.
Time frame: Within 7 days after combined immunization
Safety index-Incidence of adverse reactions
Incidence of adverse reactions at 0\~28 after combined immunization with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine.
Time frame: Within 28 days after combined immunization
Incidence of adverse reactions after a single injection of quadrivalent influenza vaccine
Incidence of adverse reactions at 0\~7 after a single injection of quadrivalent influenza vaccine.
Time frame: Within 7 days after a single injection of quadrivalent influenza vaccine
The incidence of adverse reactions after a single injection of quadrivalent influenza vaccine
Incidence of adverse reactions at 0\~28 after a single injection of quadrivalent influenza vaccine.
Time frame: Within 28 days after a single injection of quadrivalent influenza vaccine
Incidence of adverse reactions after a single injection of 23-valent pneumococcal polysaccharide vaccine
Incidence of adverse reactions at 0\~7 after a single injection of 23-valent pneumococcal polysaccharide vaccine.
Time frame: Within 7 days after a single injection of 23-valent pneumococcal polysaccharide vaccine
The incidence of adverse reactions after a single injection of 23-valent pneumococcal polysaccharide vaccine
Incidence of adverse reactions at 0\~28 after a single injection of 23-valent pneumococcal polysaccharide vaccine.
Time frame: Within 28 days after a single injection of 23-valent pneumococcal polysaccharide vaccine
Ran from Nov 2021 to primary completion in Mar 2022, 3 months.
Of 37 industry-sponsored phase 4 interventional studies under Influenza, Human, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 6. This study's 3 months is close to that.
Counting every sponsor, half of 138 studies reached it within 14 months; a quarter within 3 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.